Viva Biotech Holdings' (HKG:1873) subsidiary Viva Biotech (Shanghai) completed its registration procedures for conversion into a joint-stock company with limited liability with the State Administration for Market Regulation on Thursday, a Friday filing with the Hong Kong Exchange said.
Viva Shanghai will have an issued share capital of a little over 446.0 million yuan immediately after the completion of the conversion, of which the company is indirectly interested in 325.2 million, 72.9% of its issued share capital.
The company also appointed its co-chief financial officer Wang Zheren as the CFO of Viva Shanghai while the other co-CFO, Xiong Wei will assume responsibilities of the CFO of the group.
The drugs research and development company's shares closed 10% higher on Friday.
Price (HKD): $0.77, Change: $+0.070, Percent Change: +10.00%
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。